These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31676141)

  • 1. Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
    Spadarella G; Di Minno A; Milan G; Franco N; Polimeno M; Castaldo F; Di Minno G
    Blood Rev; 2020 Jan; 39():100618. PubMed ID: 31676141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attempting to remedy sub-optimal medication adherence in haemophilia: The rationale for repeated ultrasound visualisations of the patient's joint status.
    Di Minno A; Spadarella G; Nardone A; Mormile M; Ventre I; Morfini M; Di Minno G
    Blood Rev; 2019 Jan; 33():106-116. PubMed ID: 30146094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies using nonfactor products for patients with hemophilia and inhibitors.
    Nogami K; Shima M
    Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene therapy of haemophilia - has the cure come within reach?].
    Kaczmarek R
    Postepy Biochem; 2018 Dec; 64(4):318-322. PubMed ID: 30656916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical aspects of extended half-life products for the treatment of haemophilia.
    Lambert T; Benson G; Dolan G; Hermans C; Jiménez-Yuste V; Ljung R; Morfini M; Zupančić-Šalek S; Santagostino E
    Ther Adv Hematol; 2018 Sep; 9(9):295-308. PubMed ID: 30210757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
    Young G; Srivastava A; Kavakli K; Ross C; Sathar J; You CW; Tran H; Sun J; Wu R; Poloskey S; Qiu Z; Kichou S; Andersson S; Mei B; Rangarajan S
    Lancet; 2023 Apr; 401(10386):1427-1437. PubMed ID: 37003287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.
    Dargaud Y; Béguin S; Lienhart A; Al Dieri R; Trzeciak C; Bordet JC; Hemker HC; Negrier C
    Thromb Haemost; 2005 Mar; 93(3):475-80. PubMed ID: 15735797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin generation testing in haemophilia comprehensive care centres.
    Dargaud Y; Negrier C
    Haemophilia; 2010 Mar; 16(2):223-30. PubMed ID: 19719549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
    Chowdary P
    Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
    Waters EK; Sigh J; Friedrich U; Hilden I; Sørensen BB
    Haemophilia; 2017 Sep; 23(5):769-776. PubMed ID: 28594458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European retrospective study of real-life haemophilia treatment.
    Berntorp E; Dolan G; Hay C; Linari S; Santagostino E; Tosetto A; Castaman G; Álvarez-Román MT; Parra Lopez R; Oldenburg J; Albert T; Scholz U; Holmström M; Schved JF; Trossaërt M; Hermans C; Boban A; Ludlam C; Lethagen S
    Haemophilia; 2017 Jan; 23(1):105-114. PubMed ID: 27761962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new paradigm for personalized prophylaxis for patients with severe haemophilia A.
    Delavenne X; Ollier E; Lienhart A; Dargaud Y
    Haemophilia; 2020 Mar; 26(2):228-235. PubMed ID: 32100950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
    Björkman S; Berntorp E
    Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors.
    Brackmann HH; Schramm W; Oldenburg J; Cano V; Turecek PL; Négrier C
    Hamostaseologie; 2020 Dec; 40(5):606-620. PubMed ID: 32717751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.